|
Display Options:
|
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adenosine A2a receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyotrophic Lateral Sclerosis; Liver Diseases; Substance-Related Disorders; Parkinson Disease
ISTRADEFYLLINE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 2GZ0LIK7T4 |
| Molecule Type: Small molecule |
| Molecular Formula: C20H24N4O4 |
| Molecular Weight: 384.44 |
| AlogP: 2.12 |
| PSA: 80.28 |
| HBD: 0.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Androgen Receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Neoplasms; Prostatic Neoplasms
DAROLUTAMIDE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: X05U0N2RCO |
| Molecule Type: Small molecule |
| Molecular Formula: C19H19ClN6O2 |
| Molecular Weight: 398.85 |
| AlogP: 2.67 |
| PSA: 119.62 |
| HBD: 3.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Janus Kinase (JAK) inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Arthritis, Juvenile; Hidradenitis Suppurativa; Lupus Erythematosus, Systemic; Vitiligo; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Giant Cell Arteritis; Spondylitis, Ankylosing; Arthritis, Rheumatoid; Immune System Diseases
UPADACITINIB
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 4RA0KN46E0 |
| Molecule Type: Small molecule |
| Molecular Formula: C17H19F3N6O |
| Molecular Weight: 380.37 |
| AlogP: 2.91 |
| PSA: 78.32 |
| HBD: 2.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Retinoic acid receptor gamma agonist
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Lymphoma; Ichthyosis, Lamellar; Acne Vulgaris
TRIFAROTENE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 0J8RN2W0HK |
| Molecule Type: Small molecule |
| Molecular Formula: C29H33NO4 |
| Molecular Weight: 459.59 |
| AlogP: 5.99 |
| PSA: 70.0 |
| HBD: 2.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Fascioliasis; Helminthiasis
TRICLABENDAZOLE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 4784C8E03O |
| Molecule Type: Small molecule |
| Molecular Formula: C14H9Cl3N2OS |
| Molecular Weight: 359.67 |
| AlogP: 6.04 |
| PSA: 37.91 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glioblastoma; Glioma; Parkinson Disease; Pheochromocytoma
FLUORODOPA F 18
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 2C598205QX |
| Molecule Type: Small molecule |
| Molecular Formula: C9H10FNO4 |
| Molecular Weight: 214.18 |
| AlogP: 0.19 |
| PSA: 103.78 |
| HBD: 4.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: PI3-kinase p110-alpha subunit inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Liver Diseases; Meningioma; Multiple Myeloma; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Breast Neoplasms; Neoplasms
ALPELISIB
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 08W5N2C97Q |
| Molecule Type: Small molecule |
| Molecular Formula: C19H22F3N5O2S |
| Molecular Weight: 441.48 |
| AlogP: 3.84 |
| PSA: 101.21 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alcoholism; Alzheimer Disease; Brain Injuries; Essential Tremor; Stress Disorders, Post-Traumatic; Depressive Disorder; Status Epilepticus; Depression, Postpartum
BREXANOLONE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: S39XZ5QV8Y |
| Molecule Type: Small molecule |
| Molecular Formula: C21H34O2 |
| Molecular Weight: 318.5 |
| AlogP: 4.6 |
| PSA: 37.3 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Transthyretin stabiliser
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyloid Neuropathies, Familial; Polyneuropathies; Amyloidosis; Amyloidosis, Familial; Cardiomyopathies
TAFAMIDIS MEGLUMINE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: ZU7CF08A1A |
| Molecule Type: Small molecule |
| Molecular Formula: C21H24Cl2N2O8 |
| Molecular Weight: 503.34 |
| AlogP: 4.5 |
| PSA: 63.33 |
| HBD: 1.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Macrophage colony stimulating factor receptor inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Arthritis, Rheumatoid; Breast Neoplasms; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Neurilemmoma; Prostatic Neoplasms; Glioblastoma; Hemangiosarcoma; Hodgkin Disease; Melanoma; Prostatic Neoplasms, Castration-Resistant; Triple Negative Breast Neoplasms; Giant Cell Tumors; Synovitis, Pigmented Villonodular; Neoplasms
PEXIDARTINIB
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 6783M2LV5X |
| Molecule Type: Small molecule |
| Molecular Formula: C20H15ClF3N5 |
| Molecular Weight: 417.82 |
| AlogP: 5.23 |
| PSA: 66.49 |
| HBD: 2.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Transthyretin stabiliser
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyloid Neuropathies, Familial; Amyloidosis; Amyloidosis, Familial; Cardiomyopathies
TAFAMIDIS
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 8FG9H9D31J |
| Molecule Type: Small molecule |
| Molecular Formula: C14H7Cl2NO3 |
| Molecular Weight: 308.12 |
| AlogP: 4.5 |
| PSA: 63.33 |
| HBD: 1.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Disorders of Excessive Somnolence; Narcolepsy; Sleep Apnea, Obstructive; Attention Deficit Disorder with Hyperactivity
SOLRIAMFETOL
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 939U7C91AI |
| Molecule Type: Small molecule |
| Molecular Formula: C10H14N2O2 |
| Molecular Weight: 194.23 |
| AlogP: 0.65 |
| PSA: 78.34 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Exportin-1 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Diabetic Foot; Fallopian Tube Neoplasms; Gliosarcoma; Hematologic Neoplasms; Leukemia, Biphenotypic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Glioblastoma; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma; Lymphoma, Follicular; Melanoma; Myelodysplastic Syndromes; Primary Myelofibrosis; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Alveolar Soft Part; Severe Acute Respiratory Syndrome; Small Cell Lung Carcinoma; Thymoma; Endometrial Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Neoplasms
SELINEXOR
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 31TZ62FO8F |
| Molecule Type: Small molecule |
| Molecular Formula: C17H11F6N7O |
| Molecular Weight: 443.31 |
| AlogP: 3.39 |
| PSA: 97.62 |
| HBD: 2.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase BTK inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Leukemia; Castleman Disease; Immunoglobulin G4-Related Disease; Lupus Nephritis; Lymphoma; Neuromyelitis Optica; Purpura, Thrombocytopenic, Idiopathic; Severe Acute Respiratory Syndrome; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell; Neoplasms
ZANUBRUTINIB
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: AG9MHG098Z |
| Molecule Type: Small molecule |
| Molecular Formula: C27H29N5O3 |
| Molecular Weight: 471.56 |
| AlogP: 4.22 |
| PSA: 102.48 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Supplement
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Severe Acute Respiratory Syndrome
SELENIOUS ACID
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: F6A27P4Q4R |
| Molecule Type: Small molecule |
| Molecular Formula: H2O3Se |
| Molecular Weight: 128.97 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase JAK2 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Myeloproliferative Disorders; Leukemia, Neutrophilic, Chronic; Myelodysplastic Syndromes; Primary Myelofibrosis; Neoplasms
FEDRATINIB
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 6L1XP550I6 |
| Molecule Type: Small molecule |
| Molecular Formula: C27H36N6O3S |
| Molecular Weight: 524.69 |
| AlogP: 4.82 |
| PSA: 108.48 |
| HBD: 3.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sphingosine 1-phosphate receptor Edg-1 agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting
SIPONIMOD FUMARATE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: Z7G02XZ0M6 |
| Molecule Type: Small molecule |
| Molecular Formula: C62H74F6N4O10 |
| Molecular Weight: 1149.28 |
| AlogP: 6.77 |
| PSA: 62.13 |
| HBD: 1.0 |
| HBA: |
| #RotB: 9.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glutamate [NMDA] receptor negative allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Rhinitis, Allergic, Seasonal; Substance-Related Disorders; Neoplasms; Depressive Disorder, Major; Depressive Disorder
ESKETAMINE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 50LFG02TXD |
| Molecule Type: Small molecule |
| Molecular Formula: C13H16ClNO |
| Molecular Weight: 237.73 |
| AlogP: 2.9 |
| PSA: 29.1 |
| HBD: 1.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Calcitonin gene-related peptide type 1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Migraine Disorders
UBROGEPANT
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: AD0O8X2QJR |
| Molecule Type: Small molecule |
| Molecular Formula: C29H26F3N5O3 |
| Molecular Weight: 549.55 |
| AlogP: 3.53 |
| PSA: 104.29 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Hemoglobin HbA positive modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Acute Lung Injury; Idiopathic Pulmonary Fibrosis; Anemia, Sickle Cell
VOXELOTOR
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 3ZO554A4Q8 |
| Molecule Type: Small molecule |
| Molecular Formula: C19H19N3O3 |
| Molecular Weight: 337.38 |
| AlogP: 3.62 |
| PSA: 77.24 |
| HBD: 1.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Supplement
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FERRIC MALTOL
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: MA10QYF1Z0 |
| Molecule Type: Small molecule |
| Molecular Formula: C18H15FeO9 |
| Molecular Weight: 431.15 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Tuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary
PRETOMANID
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 2XOI31YC4N |
| Molecule Type: Small molecule |
| Molecular Formula: C14H12F3N3O5 |
| Molecular Weight: 359.26 |
| AlogP: 2.67 |
| PSA: 88.65 |
| HBD: 0.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cystic Fibrosis; Pneumonia; Bacterial Infections
LEFAMULIN
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 21904A5386 |
| Molecule Type: Small molecule |
| Molecular Formula: C28H45NO5S |
| Molecular Weight: 507.74 |
| AlogP: 3.87 |
| PSA: 109.85 |
| HBD: 3.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hyperphosphatemia; Irritable Bowel Syndrome; Constipation
TENAPANOR
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: WYD79216A6 |
| Molecule Type: Small molecule |
| Molecular Formula: C50H66Cl4N8O10S2 |
| Molecular Weight: 1145.07 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypertension; Cardiovascular Diseases
LEVAMLODIPINE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 0P6NLP6806 |
| Molecule Type: Small molecule |
| Molecular Formula: C20H25ClN2O5 |
| Molecular Weight: 408.88 |
| AlogP: 2.27 |
| PSA: 99.88 |
| HBD: 2.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FLUORODOPA
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 6WIZ27OUZ9 |
| Molecule Type: Small molecule |
| Molecular Formula: C9H10FNO4 |
| Molecular Weight: 215.18 |
| AlogP: 0.19 |
| PSA: 103.78 |
| HBD: 4.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cystic fibrosis transmembrane conductance regulator positive modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cystic Fibrosis
ELEXACAFTOR
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: RRN67GMB0V |
| Molecule Type: Small molecule |
| Molecular Formula: C26H34F3N7O4S |
| Molecular Weight: 597.66 |
| AlogP: 4.02 |
| PSA: 124.24 |
| HBD: 1.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Kelch-like ECH-associated protein 1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Sclerosis, Relapsing-Remitting; Immune System Diseases; Multiple Sclerosis
DIROXIMEL FUMARATE
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: K0N0Z40J3W |
| Molecule Type: Small molecule |
| Molecular Formula: C11H13NO6 |
| Molecular Weight: 255.23 |
| AlogP: -0.59 |
| PSA: 89.98 |
| HBD: 0.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sphingosine 1-phosphate receptor Edg-1 agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Dermatomyositis; Multiple Sclerosis, Relapsing-Remitting; Polymyositis; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Immune System Diseases
SIPONIMOD
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: RR6P8L282I |
| Molecule Type: Small molecule |
| Molecular Formula: C29H35F3N2O3 |
| Molecular Weight: 516.6 |
| AlogP: 6.77 |
| PSA: 62.13 |
| HBD: 1.0 |
| HBA: |
| #RotB: 9.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Fibroblast growth factor receptor inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Carcinoma, Hepatocellular; Liver Diseases; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Multiple Myeloma; Prostatic Neoplasms; Urogenital Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms
ERDAFITINIB
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 890E37NHMV |
| Molecule Type: Small molecule |
| Molecular Formula: C25H30N6O2 |
| Molecular Weight: 446.56 |
| AlogP: 4.18 |
| PSA: 77.33 |
| HBD: 1.0 |
| HBA: |
| #RotB: 9.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: ALK tyrosine kinase receptor inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glioma; Leukemia, Myeloid, Acute; Carcinoma, Lobular; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasms
ENTRECTINIB
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: L5ORF0AN1I |
| Molecule Type: Small molecule |
| Molecular Formula: C31H34F2N6O2 |
| Molecular Weight: 560.65 |
| AlogP: 5.03 |
| PSA: 85.52 |
| HBD: 3.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial penicillin-binding protein inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pneumonia, Bacterial; Sepsis; Infections; Urinary Tract Infections; Pneumonia; Bacterial Infections
CEFIDEROCOL
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: SZ34OMG6E8 |
| Molecule Type: Small molecule |
| Molecular Formula: C30H34ClN7O10S2 |
| Molecular Weight: 752.23 |
| AlogP: -0.18 |
| PSA: 256.9 |
| HBD: 6.0 |
| HBA: |
| #RotB: 13.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ultrasound contrast agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
AIR POLYMER-TYPE A
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: WLT3PF2KX0 |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Membrane staining aid in ophthalmic surgery
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
BRILLIANT BLUE G
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: M1ZRX790SI |
| Molecule Type: Small molecule |
| Molecular Formula: C47H48N3NaO7S2 |
| Molecular Weight: 854.04 |
| AlogP: 9.31 |
| PSA: 139.08 |
| HBD: 2.0 |
| HBA: |
| #RotB: 15.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial beta-lactamase TEM inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Communicable Diseases; Sepsis; Hematologic Neoplasms; Bacterial Infections; Pneumonia, Bacterial; Intraabdominal Infections; Pyelonephritis; Urinary Tract Infections
RELEBACTAM
×| Maximum Phase: 4 |
| First Approval: 2019 |
| UNII: 1OQF7TT3PF |
| Molecule Type: Small molecule |
| Molecular Formula: C12H20N4O6S |
| Molecular Weight: 348.38 |
| AlogP: -1.14 |
| PSA: 128.28 |
| HBD: 3.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Platelet-derived growth factor receptor alpha inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Gastrointestinal Stromal Tumors; Neoplasms
RIPRETINIB
×| Maximum Phase: 4 |
| First Approval: 2020 |
| UNII: 9XW757O13D |
| Molecule Type: Small molecule |
| Molecular Formula: C24H21BrFN5O2 |
| Molecular Weight: 510.37 |
| AlogP: 5.67 |
| PSA: 88.05 |
| HBD: 3.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |